Shire: Too Big For Its Niches
Executive Summary
When UK specialty pharmaceutical company Shire Pharmaceuticals announced its $4 billion all-share acquisition of Canada's BioChem Pharma in December, the markets punished it with a 16% drop in share price. But Shire is getting too big to acquire merely niche product opportunities.
You may also be interested in...
MedPointe and Opportunities in Specialty Pharma: Speed is Expensive
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.